EUVIMEDEUVIMED entdecken
Crossref

Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer

Xing-Jie Dai, Jiang-Wan Wu, Jin-Man Zhu, Jing-Ying Hu, Hong-Min Liu, Hui-Min Liu, Yi-Chao Zheng

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.110366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Xing-Jie Dai und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Esophageal Cancer Prevention & Treatment; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of …. Hauptthemen laut MEDLINE: Histone Demethylases, Colorectal Neoplasms, Killer Cells, Natural, Antineoplastic Agents. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Henan Provincial Science and Technology Research Project, Henan Province Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains poorly responsive to immune checkpoint blockade in a substantial proportion of patients, highlighting the need to identify druggable mechanisms that regulate tumor immune evasion. CD155, a ligand of the inhibitory receptor TIGIT, is highly expressed in CRC and contributes to impaired natural killer (NK) cell-mediated antitumor immunity. Lysine-specific demethylase 1 (LSD1/KDM1A) is a pharmacologically targetable epigenetic enzyme with emerging roles in tumor immunogenicity, but whether LSD1 inhibition modulates the CD155/TIGIT immune checkpoint axis in CRC remains unclear. In this study, we found that LSD1 and CD155 were highly expressed in CRC tissues and showed a significant positive correlation. Genetic depletion of LSD1 reduced CD155 expression at both the mRNA and protein levels in CRC cells. Importantly, pharmacological inhibition of LSD1 with two small-molecule inhibitors, CC-90011 and ORY-1001, markedly decreased CD155 expression and membrane abundance in multiple CRC cell lines. Mechanistically, LSD1 depletion or inhibition increased H3K4me2 enrichment at the CD155 promoter, suggesting that LSD1 activity is required for maintaining CD155 transcription in CRC cells. Functionally, LSD1 inhibition decreased CD155 expression and cell-surface abundance, resulting in reduced CD155/TIGIT interaction and enhanced NK cell-mediated cytotoxicity, accompanied by increased secretion of IFN-γ and TNF-α. In a CT26 syngeneic tumor model, LSD1 knockdown suppressed tumor growth and decreased CD155 expression in vivo. Collectively, these findings reveal that pharmacological inhibition of LSD1 attenuates CRC immune escape, at least in part, by epigenetically suppressing the CD155/TIGIT axis. This study provides a rationale for exploiting LSD1 inhibitors as immunomodulatory agents to enhance antitumor immunity in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone DemethylasesColorectal NeoplasmsKiller Cells, NaturalAntineoplastic AgentsReceptors, ImmunologicEnzyme InhibitorsHumansAnimalsMiceDose-Response Relationship, DrugMolecular StructureDrug Screening Assays, AntitumorStructure-Activity RelationshipCell ProliferationCell Line, TumorReceptors, Virus

Stichwörter der Autor:innen

CD155LSD1NK cell-mediated cytotoxicityTIGITcolorectal cancerimmune escape

Substanzen

Histone DemethylasesKDM1A protein, humanAntineoplastic Agentspoliovirus receptorReceptors, ImmunologicEnzyme InhibitorsReceptors, Virus

Autor:innen und Institutionen

  • State Key Laboratory of Esophageal Cancer Prevention & Treatment; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China; Key Laboratory of Henan Province for Drug Quality and Evaluatio…

Förderung

  • National Natural Science Foundation of China
  • Henan Provincial Science and Technology Research Project
  • Henan Province Natural Science Foundation
  • China Postdoctoral Science Foundation

Zitieren

APA

Dai, X. J., Wu, J. W., Zhu, J. M., Hu, J. Y., Liu, H. M., Liu, H. M., & Zheng, Y. C. (2026). Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110366

Vancouver

Dai XJ, Wu JW, Zhu JM, Hu JY, Liu HM, Liu HM, et al. Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110366

BibTeX
@article{Dai2026,
  author = {Dai, Xing-Jie and Wu, Jiang-Wan and Zhu, Jin-Man and Hu, Jing-Ying and Liu, Hong-Min and Liu, Hui-Min and Zheng, Yi-Chao},
  title = {Pharmacological inhibition of LSD1 suppresses the CD155/TIGIT immune checkpoint axis and enhances NK cell-mediated cytotoxicity in colorectal cancer},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.110366}
}
Kostenlos starten →